TP53 mutations in AML confer resistance to CAR T-cell therapy through exhaustion of CAR T-cells, and dysregulation of the mevalonate and Wnt pathways in AML and CAR T-cells, respectively. Targeting ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

It is highly expressed in glioblastoma multiforme, the most aggressive brain tumor in adults, and in its stem cells [glioblastoma stem cells (GSCs)], which contribute to treatment resistance and tumor ...

Methods Cultivate human glioma cell line U251 in vitro, induce drug-resistant cell line ... TLR4 and NF-κB monoclonal antibodies were purchased from Santa Cruz in the United States. The GAPDH internal ...

Glioblastoma (GB) is the most common intracranial invasive ... was believed to be related to rapid proliferation and cellular heterogeneity of GB cells (3, 4). In this case, the development of new ...

Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab ...

When they treated glioblastoma stem cells with other compounds developed to target clock proteins, none worked as well as SHP1705. The tests included two lines of glioblastoma stem cells ...